We performed a retrospective study to examine the protective eŠect of low-dose dexamethasone (DEX) on delayed adverse events induced by carboplatin (CBDCA)-based combination chemotherapy in patients with thoracic tumors. Low-dose DEX (4 8 mg/day) was administered on day 1 and after, in addition to a serotonin 5-HT 3 receptor antagonist. The acute adverse events (day 1) were well controlled in the patients with or without co-treatment of DEX. On the other hand, the delayed nausea, emesis, anorexia, and fatigue after day 2 failed to be controlled by 5-HT 3 antagonist alone. Co-treatment with DEX signiˆcantly suppressed the grade of the delayed adverse events during days 2 10. The mean ratio of complete protection during days 2 10 were signiˆcantly higher in the DEX-treated group compared with the non-DEX-treated group. These results reveal that low-dose DEX is a clinically eŠective treatment for the prevention of delayed adverse events induced by CBDCA-based combination chemotherapy.
INTRODUCTION
Despite the use of antiemetics, the prevention of adverse events induced by chemotherapy is still unsatisfactory and delayed nausea and emesis, in particular, remain as clinically signiˆcant problems. 1, 2) In the late 1990s, several professional organizations such as the Multinational Association of Supportive Care in Cancer, the National Comprehensive Cancer Network, and the American Society of Clinical Oncology, convened antiemetic guideline groups and published theˆndings of these expert panels. 3 7) Each of these documents was based on analyses of the available published trials and provided nearly identical recommendations. The emetic risk of chemotherapeutic agents is usually classiˆed into 4 categories: High, moderate, low, and minimal. 3, 4) The platinum chemotherapeutic agents, cisplatin (CDDP) and carboplatin (CBDCA) are categorized in high (emesis risk ＞90％ without antiemetics) and in moderate (emesis risk 30 90％ without antiemetics), respectively. 3, 4) The physiological mechanisms underlying nausea and emesis are considered to be diŠerent at the acute phase, occurring within 24 hours after chemotherapy, and the delayed phase, occurring 24 hours to several days after chemotherapy. Serotonin 5-HT 3 receptor antagonist is deˆnitely recommended against acute nausea and emesis because serotonin plays a main role at the acute phase. On the other hand, the mechanism at the delayed phase is poorly understood. 6, 8) Therefore several anti-emetic treatments are advocated: Dexamethasone (DEX), 5-HT 3 antagonist, DEX＋5-HT 3 antagonist, DEX＋neu-rokinin-1 receptor antagonist, or metoclopramide. 3 5) 5-HT 3 antagonists are without doubt the most eŠec-tive antiemetics against acute nausea and emesis. 3 7) But, more recent reviews or randomized trials have questioned the relative contribution of 5-HT 3 antagonist alone for the prevention of delayed nausea and emesis. 4,9 12) DEX is considered to be eŠective antiemetic against acute or delayed nausea and emesis, 3) although the mechanisms by which steroids exert their antiemetic activity are not fully understood. However, these evidences have been extensively obtained in high emetic risk chemotherapy using CDDP. There is little information in moderate risk chemotherapy using CBDCA. 3 5) In addition, the op- Median (range)
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ECOG: Eastern Cooperative Oncology Group, SCLC: small cell lung cancer, NSCLC: non-small cell lung cancer, CBDCA: carboplatin, AUC: area under the concentration versus time curve (mg･min/ml), VP-16: etoposide, DOC: docetaxel, DEX: dexamethasone, 5-HT3: serotonin receptor antagonist, N.S.: not signiˆcant. a) The dose of CBDCA for each patient was determined with Calvert's formula by using individual creatinine clearance (CCr) values: dose (mg)＝target AUC･(CCr＋25), b) As combination with CBDCA (day 1), VP-16 (days 1 3) was selected for SCLC, c) As combination with CBDCA (day 1), DOC (day 1) was selected for NSCLC and thymic cancer, d ) 5-HT3 was administered as the maximum dose of the package insert in Japan (i.e., ondansetron and ramosetron were administered 4 mg and 0.3 mg, until twice a day, respectively).
timal dose of DEX for delayed nausea and emesis induced by chemotherapy have not been deˆned so far. 4) Therefore, the purpose of this study was to assess the impact of DEX for the prevention of delayed adverse events induced by CBDCA-based combination chemotherapy.
METHODS

Subjects and Study Design
Seventeen Japanese inpatients with thoracic tumors underwent tri-weekly CBDCA-based combination chemotherapy and participated in monitoring the adverse events 13) in Kagawa University Hospital between April 2005 and September 2006. The characteristics of the subjects are shown in Table 1 . After obtaining written informed consent, patients conducted the adverse events monitoring using two support tools ( Table 2) modied from the basis of Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0) Japanese translated edition 14) by Japan Clinical Oncology Group/Japan Society of Clinical Oncology during thê rst 10 days after chemotherapy. 13) The grade of subjective symptoms scored by patients were checked by pharmacists to meet the above criteria 14) when they visited the bedside. Subjects meeting any of the following criteria were excluded from this study: 1) Complications inducing nausea and/or emesis (e.g., Table 2 . Two Support Tools for Adverse Events Monitoring G-CSF: Granulocyte-Colony Stimulating Factor. One scored the points of subjective symptoms by patients, and the other recorded objective symptoms by pharmacists, as shown in (A) and (B), respectively. A: the intensity range of each adverse event was grade 0 3. Grade 4, which is disabled activities of daily living, and grade 5, which is death induced by adverse event, were rarely occurred in clinical and they were excluded as it was considered that the patient can not continue to monitor adverse events in those state. B: the intensity range of each adverse event was grade 0 4 and the intensity of each adverse event and criteria range were indicated by the background coloring. The criterion range corresponds to women in this hospital. symptomatic brain metastases, ulcerative diseases, and severe hepatic dysfunction etc.); 2) use of drugs which aŠect nausea and/or emesis during investigation period, except for antiemetic (e.g., major or minor tranquilizers, corticosteroids for any other reason etc.); 3) concomitant radiotherapy during investigation period. DEX at the median (range) dose of 6 mg/day (4 8 mg/day) was intravenously administered to the patients on day 1 and after, in addition to 5-HT 3 antagonist. If a patient suŠers from nausea and emesis despite the use of antiemetics, metoclopramide (10 mg/body) is intravenously administered.
This study was approved by the Institutional Review Board of Kagawa University Hospital.
Statistical Analysis
Comparison between DEX- The ratio of complete protection against acute each adverse event (day 1) was analyzed using Fisher's exact test, and the mean ratio of complete protection against delayed each adverse event (during days 2 10) was analyzed using Student's t-test and Welch's ttest, as appropriate. All p-values were two-tailed and p＜0.05 was considered signiˆcant.
RESULTS
On day 1 nausea and emesis were well controlled in both the DEX-treated and the non-DEX-treated groups (Fig. 1) . Emesis was completely protective and only nausea of grade 1 was seen in 20％ subjects. On the other hand, there was a diŠerence between both groups in frequency and grade of nausea and emesis after day 2. The grades of nausea and emesis during days 2 10 were signiˆcantly lower in the DEXtreated group compared with the non-DEX-treated group ( p＜0.01). The mean ratio of complete protection against nausea and emesis during days 2 10 in the DEX treated group was 82.5±2.1％ and 100±0 ％ (mean±S.E.), respectively, which were signiˆcantly higher ( p＜0.01) in comparison with the non-DEX-treated group (52.2±7.4％ and 87.8±3.2 ％, respectively).
As well as nausea and emesis, anorexia and fatigue were well controlled on day 1, but not after day 2 in non-DEX-treated group (Fig. 1) . The grades of anorexia and fatigue during days 2 10 were signiˆcantly lower in the DEX-treated group compared with the non-DEX-treated group ( p＜0.01). The mean ratio of complete protection against anorexia and fatigue during days 2 10 in the DEX-treated group was 71.4±3.4％ and 76.2±5.3％, respectively, which were signiˆcantly higher ( p＜0.01) in comparison with the non-DEX-treated group (33.3±5.0％ and 46.7±3.3％, respectively). These adverse events gradually disappeared after day 10 in both groups.
Stomatitis, peripheral neuropathy, constipation, and diarrhea were well controlled and no severe adverse event (grade 4 and 5) was seen in both groups through the observation period. In addition, there was no characteristic diŠerence between both groups in the myelosuppression nadir of leukocytes, neutrophils, hemoglobin, and platelets.
DISCUSSION
The platinum chemotherapeutic agents, CDDP and CBDCA are a key drug for lung cancer, gynecologic cancer, and other malignancies. As a result of having considered insu‹cient renal function in elderly patients, 16 21) CBDCA was selected, but not CDDP. There was little information on the optimal dose of DEX for preventing the delayed nausea and emesis induced by CBDCA. This study shows that concomitant treatment of low-dose (4 8 mg/day) DEX with 5-HT 3 antagonist was eŠective for the delayed adverse events induced by CBDCA-based combination chemotherapy.
It is well-known that the presence of acute nausea and emesis is the main prognostic factor for delayed them. It goes without saying that the best way to prevent delayed nausea and emesis is to control acute them. 12) Serotonin plays a main role in acute nausea and emesis induced by chemotherapy. In fact, the acute nausea and emesis were well controlled in the non-DEX-treated group the same as in the DEXtreated group (Fig. 1) . However, more recent reviews or randomized trials have questioned the relative contribution of 5-HT 3 antagonist alone for the prevention of delayed nausea and emesis. 4,9 12) In our results (Fig. 1) , the treatment with 5-HT 3 antagonist alone (non-DEX-treated group) was less eŠective for the delayed nausea and emesis on days 2 10. Therefore, we should reconsider the routine administration of 5-HT 3 antagonist alone for delayed nausea and emesis induced by CBDCA categorized in the moderate emetic risk, although it was recommended in the guidelines. 3 5) DEX is considered to be an eŠective antiemetic agent at both acute and delayed phase, 3) although its mechanism is not fully understood. In the guidelines, the recommended dose of DEX co-administrated with 5-HT 3 antagonist for acute nausea and emesis in high and moderate emetic risk chemotherapy is 20 mg/day and 8 mg/day, respectively, whereas the optimal dose of DEX for delayed these events has not been deˆned so far. 4) Recently DEX at a dose of 8 mg/day was reported to be eŠective to delayed nausea and emesis induced by moderate emetic risk chemotherapy using other than platinum agents, cyclophosphamide, doxorubicin, epirubicin, adriamicin, and irinotecan. 12, 15, 22) Therefore, we determined the maximum dose of DEX to be 8 mg/day and decreased the dose properly depending on CBDCA dose. As a result, the co-administration of DEX at the dose of 4 8 mg/day (median; 6 mg/day) with 5-HT 3 antagonist well controlled the delayed nausea and emesis induced by CBDCA-based combination chemotherapy compared to 5-HT 3 antagonist alone (Fig. 1) . DEX also prevented the delayed anorexia and fatigue (Fig. 1) , which is in line with the results of Inoue et al. when irinotecan was used for chemotherapy. 22) In addition, the co-treatment with low-dose DEX was well tolerated. Therefore, such a low dose of DEX is recommended for preventing these delayed adverse events induced by CBDCA-based combination chemotherapy, although higher dose of DEX is needed in CDDP. 3 6) We should be careful when interpreting the results of this small retrospective study; however, our result revealed that low-dose DEX with 5-HT 3 antagonist was a clinically eŠective treatment for the prevention of delayed nausea, emesis, anorexia, and fatigue induced by CBDCA-based combination chemotherapy.
